Elon Musk says he prefers Lilly’s Mounjaro over Novo’s Ozempic

An X post from Elon Musk on Wednesday highlighted Tesla (TSLA) CEO’s newfound preference for Eli Lilly’s (NYSE:LLY) weight loss therapy Mounjaro over Novo Nordisk’s (NVO) rival product Ozempic.

Known as tirzepatide and semaglutide in generic terms, Mounjaro and Ozempic belong